Matthew Hitron
About
Matthew Hitron is a scholar working on Toxicology, Oncology and Molecular Biology.
According to data from OpenAlex, Matthew Hitron has authored 30 papers receiving a total of 224 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Toxicology, 12 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Matthew Hitron's work include Bioactive Compounds and Antitumor Agents (16 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (5 papers). Matthew Hitron is often cited by papers focused on Bioactive Compounds and Antitumor Agents (16 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (5 papers). Matthew Hitron collaborates with scholars based in United States, Canada and Japan. Matthew Hitron's co-authors include Chiang Li, Youzhi Li, William J. Edenfield, Joe Stephenson, Derek J. Jonker, Adrian Langleben, David Leggett, Wěi Li, Jeffrey G. Supko and Carlos Becerra and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.
In The Last Decade
Matthew Hitron
29 papers receiving 223 citations
Peers
Matthew Hitron
Melissa A. Yao United States
Rosa Rita Silva Italy
Candela Cives-Losada Spain
Xiaohui Yuan China
Tomohiro Takenoue Japan
Ionel Mitrica United States
Marina Shcherba United States
Li-kun Chen China
Yeshan Chen China
Itsuro Terada Japan
Citations per year, relative to Matthew Hitron Matthew Hitron (= 1×)
peers
Melissa A. Yao
Countries citing papers authored by Matthew Hitron
Since
Specialization
Citations
This map shows the geographic impact of Matthew Hitron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Hitron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Hitron more than expected).
Fields of papers citing papers by Matthew Hitron
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Matthew Hitron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Hitron. The network helps show where Matthew Hitron may publish in the future.
Co-authorship network of co-authors of Matthew Hitron
This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Hitron. A scholar is included among the top collaborators of Matthew Hitron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Hitron. Matthew Hitron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Watts, Justin M., Uma Borate, Mark J. Levis, et al.. (2025). Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia. Blood. 146(Supplement 1). 765–765.
2.
Goldlust, Samuel, Jong Hee Chang, Yoshitaka Narita, et al.. (2023). Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).. Journal of Clinical Oncology. 41(16_suppl). 2022–2022.
3.
Shah, Manish A., Takayuki Yoshino, Niall C. Tebbutt, et al.. (2022). Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study. Clinical Colorectal Cancer. 22(1). 100–110.
4.
Karol, Michael D., et al.. (2021). Mass balance and pharmacokinetics of an oral dose of 14C‐napabucasin in healthy adult male subjects. Pharmacology Research & Perspectives. 9(1). e00722–e00722.
5.
Shah, Manish A., Takayuki Yoshino, Niall C. Tebbutt, et al.. (2021). O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study. Annals of Oncology. 32. S220–S220.
6.
Karol, Michael D., et al.. (2021). Napabucasin Drug‐Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers. Clinical Pharmacology in Drug Development. 10(8). 824–839.
7.
Edenfield, William J., Carlos Becerra, Fadi S. Braiteh, et al.. (2017). A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.. Journal of Clinical Oncology. 35(15_suppl). 9553–9553.
8.
Coté, Gregory A., William J. Edenfield, Scott A. Laurie, et al.. (2017). A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma.. Journal of Clinical Oncology. 35(15_suppl). 6036–6036.
9.
Mason, Warren, Paula de Robles, Laura Borodyansky, et al.. (2017). BBI608-201GBM: A phase Ib/II clinical study of napabucasin (BBI608) in combination with temozolomide (TMZ) for adult patients with recurrent glioblastoma (GBM).. Journal of Clinical Oncology. 35(15_suppl). e13525–e13525.
10.
Edenfield, William J., Carlos Becerra, Adrian Langleben, et al.. (2017). A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer.. Journal of Clinical Oncology. 35(15_suppl). 1084–1084.
11.
Coté, Gregory M., Nicole G. Chau, Alexander I. Spira, et al.. (2017). A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor in advanced head and neck cancer.. Journal of Clinical Oncology. 35(15_suppl). 6032–6032.
12.
Becerra, Carlos, Agustin A. García, John L. Hays, et al.. (2017). A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated platinum resistant ovarian cancer.. Journal of Clinical Oncology. 35(15_suppl). 5548–5548.
13.
Jonker, Derek J., Louise Nott, Takayuki Yoshino, et al.. (2016). A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial. Annals of Oncology. 27. vi150–vi150.
14.
Bekaii‐Saab, Tanios, Sameh Mikhail, Adrian Langleben, et al.. (2016). A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer.. Journal of Clinical Oncology. 34(4_suppl). 196–196.
15.
Becerra, Carlos, Alexander I. Spira, Paul Conkling, et al.. (2016). A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.. Journal of Clinical Oncology. 34(15_suppl). 9093–9093.
16.
Becerra, Carlos, Fadi Braiteh, Alexander I. Spira, et al.. (2016). A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.. Journal of Clinical Oncology. 34(15_suppl). 1094–1094.
17.
Becerra, Carlos, Joe Stephenson, Derek J. Jonker, et al.. (2015). Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 33(15_suppl). 4069–4069.
18.
Laurie, Scott A., Derek J. Jonker, William J. Edenfield, et al.. (2014). A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2527–2527.
19.
Jonker, Derek J., Joe Stephenson, William J. Edenfield, et al.. (2014). A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2546–2546.
20.
Langleben, Adrian, Jeffrey G. Supko, Sébastien J. Hotte, et al.. (2013). A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies.. Journal of Clinical Oncology. 31(15_suppl). 2542–2542.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Melissa A. Yao Breakdown of academic impact, for papers by Rosa Rita Silva Breakdown of academic impact, for papers by Candela Cives-Losada Breakdown of academic impact, for papers by Xiaohui Yuan Breakdown of academic impact, for papers by Tomohiro Takenoue Breakdown of academic impact, for papers by Ionel Mitrica Breakdown of academic impact, for papers by Marina Shcherba Breakdown of academic impact, for papers by Li-kun Chen Breakdown of academic impact, for papers by Yeshan Chen Breakdown of academic impact, for papers by Itsuro Terada